TrialSignal
Clinical trial intelligence report
A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03869762
Status
TERMINATED
Phase
Phase II
Sponsor
Cancer Trials Ireland
Executive brief
Investment-Ready Snapshot
The DICE trial investigated the combination of Denosumab and Enzalutamide in patients with progressive metastatic castration-resistant prostate cancer and bone metastases. The study was terminated due to insufficient patient accrual, with only 7 participants enrolled.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03869762
Indication
Castration-resistant Prostate Cancer
Modality
monoclonal antibody
Target
Castration-resistant Prostate Cancer
Intervention
Xgeva, Xtandi
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.